- Home
- JLS vs MRK Comparison
JLS vs MRK Comparison
Compare JLS & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JLS | MRK |
|---|---|---|
| Founded | 2009 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.2M | 268.7B |
| IPO Year | N/A | 1994 |
Fundamental Metrics
Financial Performance| Metric | JLS | MRK |
|---|---|---|
| Price | $17.57 | $119.63 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $123.67 |
| AVG Volume (30 Days) | 14.3K | ★ 6.8M |
| Earning Date | 01-01-0001 | 04-30-2026 |
| Dividend Yield | ★ 9.33% | 2.86% |
| EPS Growth | N/A | ★ 8.01 |
| EPS | N/A | ★ 7.28 |
| Revenue | N/A | ★ $65,011,000,000.00 |
| Revenue This Year | N/A | $3.74 |
| Revenue Next Year | N/A | $5.47 |
| P/E Ratio | ★ N/A | $16.34 |
| Revenue Growth | N/A | ★ 1.31 |
| 52 Week Low | $16.80 | $75.40 |
| 52 Week High | $19.09 | $125.14 |
Technical Indicators
Market Signals| Indicator | JLS | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 30.48 | 57.94 |
| Support Level | $17.48 | $113.27 |
| Resistance Level | $18.89 | $125.14 |
| Average True Range (ATR) | 0.38 | 2.18 |
| MACD | -0.02 | 0.25 |
| Stochastic Oscillator | 14.49 | 81.80 |
Price Performance
Historical ComparisonAbout JLS Nuveen Mortgage and Income Fund
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. The Fund's investment objective is to provide a high level of current income.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).